Tools   Select Another Resource Report Type

http://clinicaltrials.gov/show/NCT00143949

Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained.

Proper citation: Renin Angiotensin System Study (RRID:SCR_013385) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/36

Data set and biosepecimens of a multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally. Neither injected nor oral insulin at the doses used were observed to delay or prevent diabetes, although further studies are needed to test whether oral insulin can delay diabetes in people in the intermediate risk group with high titers of insulin autoantibodies.

Proper citation: Diabetes Prevention Type 1 (RRID:SCR_001467) Copy   

•   Source: SciCrunch Registry

http://dknet.org/

The NIDDK Information Network (dkNET) is a community-based network to serve needs of basic and clinical investigators that includes large pools of data and research resources relevant to mission of National Institute of Diabetes and Digestive and Kidney Disease.

Proper citation: NIDDK Information Network (dkNET) (RRID:SCR_001606) Copy   

•   Source: SciCrunch Registry

https://diabetes.med.umich.edu/partners/michigan-center-diabetes-translational-research-mcdtr

Multidisciplinary unit of the University of Michigan funded by National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health. MCDTR is one of seven NIH Centers funded to focus on type 2 translational research in diabetes with mission to establish, promote, and enhance multidisciplinary collaboration among researchers directed at prevention and control of diabetes, its complications, and comorbidities, by providing access to specialized expertise and resources.

Proper citation: Michigan Center for Diabetes Translational Research (RRID:SCR_015187) Copy   

•   Source: SciCrunch Registry

http://www.oucom.ohiou.edu/Biorepository/biorepository_inventory.htm

Plasma and cell fractions obtained from patients with Diabetes and endocrine diseases and their first degree relatives who agreed to participate in the development of the biorepository. Plasma is aliquoted into multiple specimen containers and stored at -80C. Cell fractions are subjected to DNA and RNA fractionation, aliquoted into multiple specimen containers, and frozen at -70 to -80 degrees centigrade. Anyone who would like to obtain samples from the Biorepository must provide evidence that they have adequate training in the use of bloodborne pathogens, as outlined by OSHA. The investigator must agree to indemnify and hold harmless the Ohio University Diabetes/Endocrine Diseases Biorepository, the Appalachian Rural health Institute, and the Ohio University College of Osteopathic Medicine from any claims, liability, costs, and damages.

Proper citation: Ohio U Diabetes Endocrine Biorepository (RRID:SCR_013435) Copy   

•   Source: SciCrunch Registry

http://nmri.niddk.nih.gov/

Communication network of current and potential biomedical research investigators and technical personnel from traditionally under-served communities: African American, Hispanic American, American Indian, Alaskan Native, Native Hawaiian, and other Pacific Islanders. The major objective of the network is to encourage and facilitate participation of members of underrepresented racial and ethnic minority groups in the conduct of biomedical research in the fields of diabetes, endocrinology, metabolism, digestive diseases, nutrition, kidney, urologic and hematologic diseases. A second objective is to encourage and enhance the potential of the underrepresented minority investigators in choosing a biomedical research career in these fields. An important component of this network is promotion of two-way communications between network members and the NIDDK.

Proper citation: Network of Minority Health Research Investigators (RRID:SCR_006589) Copy   

•   Source: SciCrunch Registry

http://www.diabetes.niddk.nih.gov/

Information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established to increase knowledge and understanding about diabetes among patients, health care professionals, and the general public: online, in booklets and fact sheets, by email, and over the phone. To carry out this mission, NDIC works closely with NIDDK''''s Diabetes Research and Training Centers; the National Diabetes Education Program (NDEP); professional, patient, and voluntary associations; Government agencies; and State health departments to identify and respond to informational needs about diabetes and its management. NDIC provides the following informational products and services: * Response to inquiries about diabetes, ranging from information about available patient and professional education materials to statistical data. By phone (8:30 a.m. to 5 p.m. eastern time, M-F), fax, mail, and email. * Publications about diabetes, provided free of copyright, in varying reading levels. Available online or as booklets and brochures. NDIC also sends publications to health fairs and community events. * Referrals to health professionals through the National Library of Medicine''''s MEDLINEplus includes a consumer-friendly listing of organizations that will assist you in your search for physicians and other health professionals. * Exhibits at professional meetings specific to diabetes, as well as cross-cutting professional meetings. NDIC exhibits at 12 professional meetings, each year, including American Diabetes Association Postgraduate Course, American College of Physicians, CDC Diabetes Translation Conference, American Academy of Physician Assistants, American Diabetes Association, American Association of Diabetes Educators, and American Dietetic Association.

Proper citation: National Diabetes Information Clearinghouse (RRID:SCR_006702) Copy   

•   Source: SciCrunch Registry

https://professional.diabetes.org/content-page/covid-19

Web page created by American Diabetes Association. Contains resources and information about COVID-19 for diabetes professionals and patients. ADA also provides online forum, webinar series and podcast. Online forum to exchange questions, answers, and best practices with leading clinicians from diabetes community. All ADA members can contribute, and any interested health professional can read forum and responses.

Proper citation: American Diabetes Association COVID-19 Resources and Webinar Series (RRID:SCR_018346) Copy   

•   Source: SciCrunch Registry

http://secrepedia.org

Encyclopedia of white and brown adipocyte secretome in mouse models and humans as key prerequisite to elucidating role of these mediators in normal physiology and disease.

Proper citation: Secrepedia (RRID:SCR_022590) Copy   

•   Source: SciCrunch Registry

https://www.mitochondriasci.com/mitochondria-related-diseases.html

Creative Biogene provides comprehensive range of services and products to assist researchers in mitochondrial assays and studies. Service to validate and explore pathogenesis of mitochondria associated diseases and possible interventions.

Proper citation: Creative Biogene Mitochondria Related Diseases (RRID:SCR_022080) Copy   

•   Source: SciCrunch Registry

http://www.grc.nia.nih.gov/

A research program of the NIA which focuses on neuroscience, aging biology, and translational gerontology. The central focus of the program's research is understanding age-related changes in physiology and the ability to adapt to environmental stress, and using that understanding to develop insight about the pathophysiology of age-related diseases. The IRP webpage provides access to other NIH resources such as the Biological Biochemical Image Database, the Bioinformatics Portal, and the Baltimore Longitudinal Study of Aging., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Intramural Research Program (RRID:SCR_012734) Copy   

•   Source: SciCrunch Registry

https://www.cellhub.org/

Cell repository that aims to share cell samples for the scientific advancement of Type 1 Diabetes research. Cell lines can be requested from their cell bank inventory.

Proper citation: Helmsley Cellular Research Hub (RRID:SCR_015546) Copy   

•   Source: SciCrunch Registry

https://www.sanger.ac.uk/collaboration/sequencing-idd-regions-nod-mouse-genome/

Genetic variations associated with type 1 diabetes identified by sequencing regions of the non-obese diabetic (NOD) mouse genome and comparing them with the same areas of a diabetes-resistant C57BL/6J reference mouse allowing identification of single nucleotide polymorphisms (SNPs) or other genomic variations putatively associated with diabetes in mice. Finished clones from the targeted insulin-dependent diabetes (Idd) candidate regions are displayed in the NOD clone sequence section of the website, where they can be downloaded either as individual clone sequences or larger contigs that make up the accession golden path (AGP). All sequences are publicly available via the International Nucleotide Sequence Database Collaboration. Two NOD mouse BAC libraries were constructed and the BAC ends sequenced. Clones from the DIL NOD BAC library constructed by RIKEN Genomic Sciences Centre (Japan) in conjunction with the Diabetes and Inflammation Laboratory (DIL) (University of Cambridge) from the NOD/MrkTac mouse strain are designated DIL. Clones from the CHORI-29 NOD BAC library constructed by Pieter de Jong (Children's Hospital, Oakland, California, USA) from the NOD/ShiLtJ mouse strain are designated CHORI-29. All NOD mouse BAC end-sequences have been submitted to the International Nucleotide Sequence Database Consortium (INSDC), deposited in the NCBI trace archive. They have generated a clone map from these two libraries by mapping the BAC end-sequences to the latest assembly of the C57BL/6J mouse reference genome sequence. These BAC end-sequence alignments can then be visualized in the Ensembl mouse genome browser where the alignments of both NOD BAC libraries can be accessed through the Distributed Annotation System (DAS). The Mouse Genomes Project has used the Illumina platform to sequence the entire NOD/ShiLtJ genome and this should help to position unaligned BAC end-sequences to novel non-reference regions of the NOD genome. Further information about the BAC end-sequences, such as their alignment, variation data and Ensembl gene coverage, can be obtained from the NOD mouse ftp site.

Proper citation: Sequencing of Idd regions in the NOD mouse genome (RRID:SCR_001483) Copy   

•   Source: SciCrunch Registry

http://www.type2diabetesgenetics.org/

Portal and database of DNA sequence, functional and epigenomic information, and clinical data from studies on type 2 diabetes and analytic tools to analyze these data. .Provides data and tools to promote understanding and treatment of type 2 diabetes and its complications. Used for identifying genetic biomarkers correlated to Type 2 diabetes and development of novel drugs for this disease.

Proper citation: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) (RRID:SCR_003743) Copy   

•   Source: SciCrunch Registry

http://www.diagram-consortium.org/

Consortium of researchers aiming to characterize the genetic basis of type 2 diabetes with a principal focus on samples of European descent. DIAGRAM also features a database of DIAGRAM publications and diabetes-related research data.

Proper citation: DIAGRAM (RRID:SCR_015675) Copy   

•   Source: SciCrunch Registry

http://www.uc.edu/labs/mmpc.html

Research center that provides metabolic and physiologic phenotyping services for mouse models of diabetes, diabetic complications, obesity and related disorders. It specializes in the immunological aspects of Type I diabetes, measurement of various glucose and lipid metabolism parameters relevant to Type II diabetes as well as diabetic complications such as heart disease and obesity.

Proper citation: MMPC-University of Cincinnati Medical Center (RRID:SCR_015367) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/mmpc

Research center whose mission is to advance research in the area of diabetes by providing experimental tools to the scientific community for phenotyping mouse transgenic models of diabetes and related disorders.

Proper citation: MMPC-Vanderbilt University School of Medicine (RRID:SCR_015374) Copy   

•   Source: SciCrunch Registry

http://www.perl-study.org

PERL is a clinical trial for people with type 1 diabetes who have early signs of kidney problems. Its goal is to test a new way to reduce loss of kidney function using a safe and inexpensive medicine.

Proper citation: Preventing Early Renal Loss in Diabetes (PERL) (RRID:SCR_015862) Copy   

•   Source: SciCrunch Registry

https://hirnetwork.org/coordinating_group/hirec

The Bioinformatics Center is located within the Department of Diabetes and Cancer Discovery Science at City of Hope and was established in 2014 to support the Human Islet Research Network (HIRN). The overall objective of the Bioinformatics Center is to advance type 1 diabetes knowledge generated through HIRN by providing the bioinformatics capability and infrastructure needed to support the Network. To achieve this goal, the Bioinformatics Center provides investigators with tools, processes, and methods to facilitate long term sharing, maintenance, and management of HIRN developed resources, including datasets, technologies, documents, and bioreagents. Collaboration and communication are cultivated through consultation and outreach activities. In 2019, HIRN received funding to continue HIRN Coordinating Center (CC) and Bioinformatics Center (BC) as Human Islet Research Enhancement Center (HIREC).

Proper citation: HIRN Bioinformatics Center (RRID:SCR_016203) Copy   

•   Source: SciCrunch Registry

https://www.pbcconsortium.org/

Portal to provide a repository for beta-cell data, to connect researchers from different backgrounds interested in contributing data, models and/or ideas for new insights into beta-cell biology. Used to understand beta-cell biology and diabetes through a cross-disciplinary approach for the assembly of spatiotemporal multi-scale whole cell models of human pancreatic beta-cells.

Proper citation: The Pancreatic Beta-Cell Consortium (RRID:SCR_016328) Copy   

•   Source: SciCrunch Registry